EFFICACY OF TERIPARATIDE TREATMENT OF REDUCED BMD IN LIVER TRANSPLANT PATIENTS

特立帕肽治疗肝移植患者骨密度降低的疗效

• 批准号: 7375430
• 负责人: LAURA D CARBONE
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375430
• 关键词: EFFICACY; TERIPARATIDE; TREATMENT; REDUCED; BMD

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This proposal will test the hypothesis that teriparatide is a safe and effective therapy for bone loss in patients with liver disease awaiting orthotopic liver transplant.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。该提案将检验特立帕肽是一种安全有效的治疗等待原位肝移植的肝病患者骨质流失的假设。